Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patients
12/29/2020
Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pivotal trials, Reuters reports.
Meanwhile, the efficacy demonstrated after one year of treatment (https://bit.ly/2VHCGdw) was maintained, Dr. Rahul N. Khurana of Northern California Retina Vitreous Associates, in Mountain View, and colleagues report in Ophthalmology.